메뉴 건너뛰기




Volumn 46, Issue 1, 2006, Pages 99-104

Cyclophosphamide disposition in an anephric child

Author keywords

Anephric; Cyclophosphamide; Pharmacokinetic; Renal

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CARBOXYETHYLPHOSPHORAMIDE MUSTARD; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; LABETALOL; LISINOPRIL; LORAZEPAM; MESNA; ONDANSETRON; PHOSPHORAMIDE MUSTARD; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

EID: 28844507982     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20558     Document Type: Article
Times cited : (11)

References (41)
  • 1
    • 0035424844 scopus 로고    scopus 로고
    • Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study
    • Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469.
    • (2001) J Clin Oncol , vol.19 , pp. 3463-3469
    • Saylors III, R.L.1    Stine, K.C.2    Sullivan, J.3
  • 2
    • 18744413524 scopus 로고    scopus 로고
    • Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV
    • Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78-84.
    • (2003) J Clin Oncol , vol.21 , pp. 78-84
    • Breneman, J.C.1    Lyden, E.2    Pappo, A.S.3
  • 3
    • 0036250461 scopus 로고    scopus 로고
    • Treatment of refractory osteosarcoma with fractionated Cyclophosphamide and etoposide
    • Rodriguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated Cyclophosphamide and etoposide. J Pediatr Hematol Oncol 2002;24:250-255.
    • (2002) J Pediatr Hematol Oncol , vol.24 , pp. 250-255
    • Rodriguez-Galindo, C.1    Daw, N.C.2    Kaste, S.C.3
  • 4
    • 0042914721 scopus 로고    scopus 로고
    • CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin lymphoma
    • Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin lymphoma. J Clin Oncol 2003;21:3041-3050.
    • (2003) J Clin Oncol , vol.21 , pp. 3041-3050
    • Doorduijn, J.K.1    Van Der Holt, B.2    Van Imhoff, G.W.3
  • 5
    • 0037687355 scopus 로고    scopus 로고
    • Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
    • Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
    • (2003) J Clin Oncol , vol.21 , pp. 1431-1439
    • Citron, M.L.1    Berry, D.A.2    Cirrincione, C.3
  • 6
    • 0029863162 scopus 로고    scopus 로고
    • Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients
    • Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-1494.
    • (1996) J Clin Oncol , vol.14 , pp. 1484-1494
    • Slattery, J.T.1    Kalhorn, T.F.2    McDonald, G.B.3
  • 8
    • 1842844017 scopus 로고    scopus 로고
    • Pharmacological Considerations of Primary Alkylators
    • Andersson B, Murray D, editors. Boston: Kluwer Academic Publishers
    • McCune JS, Slattery JT. Pharmacological Considerations of Primary Alkylators. In: Andersson B, Murray D, editors. Clinically relevant resistance in cancer chemotherapy. Boston: Kluwer Academic Publishers; 2002. p 323-337.
    • (2002) Clinically Relevant Resistance in Cancer Chemotherapy , pp. 323-337
    • McCune, J.S.1    Slattery, J.T.2
  • 9
    • 0026100542 scopus 로고
    • Clinical pharmacokinetics of cyclophosphamide
    • Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991;20:194-208.
    • (1991) Clin Pharmacokinet , vol.20 , pp. 194-208
    • Moore, M.J.1
  • 11
    • 0017264779 scopus 로고
    • The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide
    • Mouridsen HT, Faber O, Skovsted L. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide. Cancer 1976;37:665-670.
    • (1976) Cancer , vol.37 , pp. 665-670
    • Mouridsen, H.T.1    Faber, O.2    Skovsted, L.3
  • 12
    • 0028801467 scopus 로고
    • Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation [published erratum appears in Cancer Res 1995 Apr 1;55(7):1600]
    • Chen TL, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation [published erratum appears in Cancer Res 1995 Apr 1;55(7):1600]. Cancer Res 1995;55:810-816.
    • (1995) Cancer Res , vol.55 , pp. 810-816
    • Chen, T.L.1    Passos-Coelho, J.L.2    Noe, D.A.3
  • 13
    • 0031657664 scopus 로고    scopus 로고
    • Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients
    • Ren S, Kalhorn TF, McDonald GB, et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998;64:289-301.
    • (1998) Clin Pharmacol Ther , vol.64 , pp. 289-301
    • Ren, S.1    Kalhorn, T.F.2    McDonald, G.B.3
  • 14
    • 0030799414 scopus 로고    scopus 로고
    • Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes
    • Ren S, Yang JS, Kalhorn TF, et al. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-4235
    • (1997) Cancer Res , vol.57 , pp. 4229-4235
    • Ren, S.1    Yang, J.S.2    Kalhorn, T.F.3
  • 15
    • 0026667068 scopus 로고
    • Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde
    • Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992;43:2453-2469.
    • (1992) Biochem Pharmacol , vol.43 , pp. 2453-2469
    • Dockham, P.A.1    Lee, M.O.2    Sladek, N.E.3
  • 16
    • 0026751449 scopus 로고
    • Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients
    • Tasso MJ, Boddy AV, Price L, et al. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 1992;30:207-211.
    • (1992) Cancer Chemother Pharmacol , vol.30 , pp. 207-211
    • Tasso, M.J.1    Boddy, A.V.2    Price, L.3
  • 17
    • 0042912912 scopus 로고    scopus 로고
    • Clinical and cellular pharmacology in relation to solid tumours of childhood
    • Estlin EJ, Veal GJ. Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev 2003;29:253-273.
    • (2003) Cancer Treat Rev , vol.29 , pp. 253-273
    • Estlin, E.J.1    Veal, G.J.2
  • 18
    • 0037370735 scopus 로고    scopus 로고
    • Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
    • McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-2048.
    • (2003) Blood , vol.101 , pp. 2043-2048
    • McDonald, G.B.1    Slattery, J.T.2    Bouvier, M.E.3
  • 19
    • 0842311624 scopus 로고    scopus 로고
    • Cyclophosphamide metabolism in children with non-Hodgkin lymphoma
    • Yule SM, Price L, McMahon AD, et al. Cyclophosphamide metabolism in children with non-Hodgkin lymphoma. Clin Cancer Res 2004;10:455-460.
    • (2004) Clin Cancer Res , vol.10 , pp. 455-460
    • Yule, S.M.1    Price, L.2    McMahon, A.D.3
  • 20
    • 0016705622 scopus 로고
    • Pharmacokinetics of cyclophosphamide in renal failure
    • Mouridsen HT, Jacobsen E. Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol Toxicol 1975;36:409-414.
    • (1975) Acta Pharmacol Toxicol , vol.36 , pp. 409-414
    • Mouridsen, H.T.1    Jacobsen, E.2
  • 21
    • 0019440332 scopus 로고
    • Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites
    • Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981;19:443-451.
    • (1981) Eur J Clin Pharmacol , vol.19 , pp. 443-451
    • Juma, F.D.1    Rogers, H.J.2    Trounce, J.R.3
  • 22
    • 0018596314 scopus 로고
    • The disposition of cyclophosphamide in a group of myeloma patients
    • Bramwell V, Calvert RT, Edwards G, et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979;3:253-259.
    • (1979) Cancer Chemother Pharmacol , vol.3 , pp. 253-259
    • Bramwell, V.1    Calvert, R.T.2    Edwards, G.3
  • 23
    • 0036226436 scopus 로고    scopus 로고
    • Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency
    • Haubitz M, Bohnenstengel F, Brunkhorst R, et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002;61:1495-1501.
    • (2002) Kidney Int , vol.61 , pp. 1495-1501
    • Haubitz, M.1    Bohnenstengel, F.2    Brunkhorst, R.3
  • 24
    • 0031715170 scopus 로고    scopus 로고
    • Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis
    • Bischoff ME, Blau W, Wagner T, et al. Total body irradiation and cyclophosphamide is a conditioning regimen for unrelated bone marrow transplantation in a patient with chronic myelogenous leukemia and renal failure on hemodialysis. Bone Marrow Transplant 1998;22:591-593.
    • (1998) Bone Marrow Transplant , vol.22 , pp. 591-593
    • Bischoff, M.E.1    Blau, W.2    Wagner, T.3
  • 25
    • 0032951656 scopus 로고    scopus 로고
    • Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease
    • Perry JJ, Fleming RA, Rocco MV, et al. Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease. Bone Marrow Transplant 1999;23:839-842.
    • (1999) Bone Marrow Transplant , vol.23 , pp. 839-842
    • Perry, J.J.1    Fleming, R.A.2    Rocco, M.V.3
  • 26
    • 0017855921 scopus 로고
    • Haemodialysis during cyclophosphamide treatment
    • Bending MR, Finch RE. Haemodialysis during cyclophosphamide treatment. Br Med J 1978;1:1145-1146.
    • (1978) Br Med J , vol.1 , pp. 1145-1146
    • Bending, M.R.1    Finch, R.E.2
  • 27
    • 0019491166 scopus 로고
    • Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cells, and dialysate measurements for cyclophosphamide
    • Wang LH, Lee CS, Majeske BL, et al. Clearance and recovery calculations in hemodialysis: Application to plasma, red blood cells, and dialysate measurements for cyclophosphamide. Clin Pharmacol Ther 1981;29:365-372.
    • (1981) Clin Pharmacol Ther , vol.29 , pp. 365-372
    • Wang, L.H.1    Lee, C.S.2    Majeske, B.L.3
  • 28
    • 2042537638 scopus 로고
    • Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites
    • German
    • Wagner T, Heydrich D, Bartels H, et al. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites]. Arzneimittelforschung 1980;30:1588-1592. German.
    • (1980) Arzneimittelforschung , vol.30 , pp. 1588-1592
    • Wagner, T.1    Heydrich, D.2    Bartels, H.3
  • 29
    • 0028609968 scopus 로고
    • Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508
    • Chan KK, Hong PS, Tutsch K, et al. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res 1994;54:6421-6429.
    • (1994) Cancer Res , vol.54 , pp. 6421-6429
    • Chan, K.K.1    Hong, P.S.2    Tutsch, K.3
  • 30
    • 0030223023 scopus 로고    scopus 로고
    • Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide kinetics in patients receiving high-dose Cyclophosphamide chemotherapy
    • Anderson LW, Chen TL, Colvin OM, et al. Cyclophosphamide and 4-Hydroxycyclophosphamide/Aldophosphamide kinetics in patients receiving high-dose Cyclophosphamide chemotherapy. Clin Cancer Res 1996;2:1481-1487.
    • (1996) Clin Cancer Res , vol.2 , pp. 1481-1487
    • Anderson, L.W.1    Chen, T.L.2    Colvin, O.M.3
  • 31
    • 0031934032 scopus 로고    scopus 로고
    • Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group Study
    • Saylors RL 3rd, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 1998;16:945-952.
    • (1998) J Clin Oncol , vol.16 , pp. 945-952
    • Saylors III, R.L.1    Stewart, C.F.2    Zamboni, W.C.3
  • 32
    • 0032846456 scopus 로고    scopus 로고
    • Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen- phosphorus detection
    • Kalhorn TF, Ren S, Howald WN, et al. Analysis of cyclophosphamide and five metabolites from human plasma using liquid chromatography-mass spectrometry and gas chromatography-nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 1999;732:287-298.
    • (1999) J Chromatogr B Biomed Sci Appl , vol.732 , pp. 287-298
    • Kalhorn, T.F.1    Ren, S.2    Howald, W.N.3
  • 34
    • 0037370735 scopus 로고    scopus 로고
    • Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
    • McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101:2043-2048.
    • (2003) Blood , vol.101 , pp. 2043-2048
    • McDonald, G.B.1    Slattery, J.T.2    Bouvier, M.E.3
  • 35
    • 14444271073 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer
    • Gilbert CJ, Petros WP, Vredenburgh J, et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother Pharmacol 1998;42:497-503.
    • (1998) Cancer Chemother Pharmacol , vol.42 , pp. 497-503
    • Gilbert, C.J.1    Petros, W.P.2    Vredenburgh, J.3
  • 36
    • 0032801763 scopus 로고    scopus 로고
    • Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics
    • Cagnoni PJ, Matthes S, Day TC, et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant 1999;24:1-4.
    • (1999) Bone Marrow Transplant , vol.24 , pp. 1-4
    • Cagnoni, P.J.1    Matthes, S.2    Day, T.C.3
  • 37
    • 0028890757 scopus 로고
    • Cyclophosphamide metabolism in children
    • Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide metabolism in children. Cancer Res 1995;55:803-809.
    • (1995) Cancer Res , vol.55 , pp. 803-809
    • Yule, S.M.1    Boddy, A.V.2    Cole, M.3
  • 38
    • 0034743355 scopus 로고    scopus 로고
    • Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion
    • Yule SM, Price L, Cole M, et al. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol 2001;47:222-228.
    • (2001) Cancer Chemother Pharmacol , vol.47 , pp. 222-228
    • Yule, S.M.1    Price, L.2    Cole, M.3
  • 39
    • 0033736153 scopus 로고    scopus 로고
    • In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone
    • McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-366.
    • (2000) Clin Pharmacol Ther , vol.68 , pp. 356-366
    • McCune, J.S.1    Hawke, R.L.2    LeCluyse, E.L.3
  • 40
    • 0017837582 scopus 로고
    • Haemodialysis during cyclophosphamide treatment
    • Milsted RA, Jarman M. Haemodialysis during cyclophosphamide treatment. Br Med J 1978;1:820-821.
    • (1978) Br Med J , vol.1 , pp. 820-821
    • Milsted, R.A.1    Jarman, M.2
  • 41
    • 0030045849 scopus 로고    scopus 로고
    • Cyclophosphamide pharmacokinetics in children
    • Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 1996;41:13-19.
    • (1996) Br J Clin Pharmacol , vol.41 , pp. 13-19
    • Yule, S.M.1    Boddy, A.V.2    Cole, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.